Literature DB >> 170297

Epinephrine-induced alterations in urinary cyclic AMP in hyper- and hypothyroidism.

R B Guttler, J W Shaw, C L Otis, J T Nicologg.   

Abstract

Although ratios of urinary cyclic AMP (cAMP) to creatinine were found in this study to be elevated in hyperthyroidism, as previously reported, this elevation appears to result primarily from a decrease in the rate of urinary creatinine excretion associated with the hyperthyroid state and not to be due to an increase in the urinary cAMP production rate. Indeed, there was no significant alteration observed in the urinary cAMP excretion found in 15 hyper-, 12 eu-, and 5 hypothyroid subjects. However, a slight, but significant increase in the 24-hour urinary cAMP excretion was noted in ambulating hyperthyroid subjects (8.5 +/- 2.4 muMol/day; normal 5.2 +/- 1.6 muMol/day; P less than .05). In contrast, the effect of the infusion of 0.05 mug/kg/min of epinephrine over a 2-hour period, resulted in a significantly greater rise in urinary cAMP excretion in hyperthyroid patients (0.83 +/- 0.07 muMol/h) compared to euthyroid subjects (0.53 +/- 0.4 muMol/h; P less than .005). Furthermore, hypothyroid subjects had no significant rise in urinary cAMP excretion after epinephrine infusion (P less than .001). Cardiovascular end-organ response to the epinephrine infusion was also greater in the hyperthyroid subjects and virtually absent in the hypothyroid group. These results suggest that there may be a significant alteration in the cAMP generating systems in states of thyroid hormone excess or insufficiency, and that provocative stimuli, such as epinephrine, may have its end-organ response modified by thyroid hormone effects on adenylate cyclase-cyclic AMP generating systems.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 170297     DOI: 10.1210/jcem-41-4-707

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Urinary excretion of cyclic AMP in bacterial infections.

Authors:  W J Sibbald; V M Sardesai; A Short; R F Wilson
Journal:  Intensive Care Med       Date:  1979-05       Impact factor: 17.440

2.  Investigation of the usefulness of the plasma adenosine 3' 5' - cyclic monophosphate response to glucagon in thyroid disease.

Authors:  S Mac Neil; G N Hendy; H Amirrasooli; P R Daggett; S Tomlinson
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256

3.  Increased fat and skeletal muscle beta-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis.

Authors:  S B Liggett; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

4.  Studies on metabolic alterations after a mixed meal and during a 39-hour fast in thyrotoxicosis.

Authors:  G Federspil; M Zaccaria; N Sicolo; C De Palo; E Zago; A Boninsegna; M Bevilacqua; C Scandellari
Journal:  J Endocrinol Invest       Date:  1979 Apr-Jun       Impact factor: 4.256

5.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.

Authors:  A E Broadus; J E Mahaffey; F C Bartter; R M Neer
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

6.  Plasma and urine cyclic nucleotide levels in patients with hyperthyroidism and hypothyroidism.

Authors:  M Peracchi; F Bamonti-Catena; L Lombardi; E Reschini; V Toschi; A T Maiolo; E E Polli
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

7.  Triiodothyronine-induced thyrotoxicosis increases mononuclear leukocyte beta-adrenergic receptor density in man.

Authors:  A M Ginsberg; W E Clutter; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.